Cost-effectiveness of ethyl-eicosapentaenoic acid in the treatment of bipolar disorder

Therapeutic Advances in Psychopharmacology

Volumn 3, Issue 2, 2013, Pages 73-81

  Cheema, Nadir ^a   Frangou, Sophia ^b   McCrone, Paul ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Bipolar; cost effectiveness; ethyl eicosapentaenoic acid (ethyl EPA); Markov model

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; ETHYL EICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID; NEUROLEPTIC AGENT; PLACEBO; UNCLASSIFIED DRUG; VALPROIC ACID;

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HAMILTON SCALE; HUMAN; MALE; ONSET AGE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT INDICATION;

EID: 84997945655     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125312464105     Document Type: Article

References (14)

1. Bridle C. Palmer S. Bagnall A. Darba J. Duffy S. Sculpher M. et al. (2004) A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. Health Technol Assess 8: 19.
2. Calvert N. Burch S. Fu A. et al. (2006) The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder. J Manag Care Pharm 12: 322–330.
3. Das Gupta R. Guest J. (2002) Annual cost of bipolar disorder to UK society. Br J Psychiatry 180: 227–233.
4. Fajutrao L. Paulsson B. Liu S. Locklear J. (2009) Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis. Clin Therapeut 31: 1456–1468.
5. Frangou S. Lewis M. McCrone P. (2006) Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry 188: 46–50.
6. Hamilton (1960) A rating scale for depression. Journal of Neurol Neurosurg Psychiatry 23: 56–62.
7. Maj M. Pirozzi R. Formicola A. Bartoli L. Bucci P. (2000) Reliability and validity of the DSM-IV diagnostic category of schizoaffective disorder: preliminary data. J Affect Disord 57: 95–98.
8. McKendrick J. Cerri K. Lloyd A. D’Ausilio A. Dando S. Chinn C. (2007) Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom. J Psychopharmacol 21: 588–596.
9. National Collaborating Centre for Mental Health (2006) Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. London: The British Psychological Society and Gaskell.
10. National Institute for Health and Clinical Excellence (2006) NICE Bipolar Guideline CG38.
11. Netten A. Rees T. Harrison G. (2001) Unit Costs of Health and Social Care. Canterbury: PSSRU.
12. Revicki D. Hanlon J. Martin S. Gyulai L. Ghaemi S. Lynch F. et al. (2005) Patient-based utilities for bipolar disorder-related health states. J Affect Disord 78: 203–210.
13. Soares-Weiser K. Bravo V. Beynon S. Dunn G. Barbieri M. Duffy S. et al. (2007) A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess 11: 39.
14. Tengs T. Wallace A. (2000) One thousand health-related quality-of-life estimates. Med Care 38: 583–637.